Background-Heart valve disease (HVD) is frequent in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Thus, our objective was to estimate the risk of HVD, including Libman-Sacks endocarditis, associated with aPL in patients with SLE. Methods and Results-Studies were selected if they investigated the association between aPL and HVD in SLE patients and if aPL-negative patients were included for comparison. Data sources were MEDLINE, Embase, Cochrane Library, hand search, contact with investigators, and reference lists of studies, without language restrictions. Data on study and patient characteristics, risk estimates, and study quality were independently extracted by 2 investigators. Pooled effect estimates were obtained by using the DerSimonian-Laird method. Of 234 identified abstracts, 23 primary studies (15 cross-sectional, 7 cohort, 1 case-control) met inclusion criteria, including 1656 SLE patients and 508 cases of HVD. Compared with SLE patients without aPL (nϭ988), the overall pooled odds ratios for HVD and Libman-Sacks endocarditis in aPL-positive patients (nϭ668) were 3.13 (95% confidence interval, 2.31 to 4.24) and 3.51 (95% confidence interval, 1.93 to 6.38), respectively. The risk of HVD depending on aPL subtypes was the highest for lupus anticoagulant at 5.88 (95% confidence interval, 2.92 to 11.84) and IgG anticardiolipin antibodies at 5.63 (95% confidence interval, 3.53 to 8.97).
A ntiphospholipid antibodies (aPL) may be considered either as risk factors for arterial or venous thrombosis as well as recurrent fetal losses [1] [2] [3] [4] [5] [6] or as markers of the so-called antiphospholipid syndrome (APS). APS is characterized by venous or arterial thromboses and obstetric morbidity associated with persistent aPL according to the classification criteria. 7 APS may exist in its primary form but may also be associated with various disorders, especially systemic lupus erythematosus (SLE). 7 Heart valve disease (HVD) (defined by vegetation, valve thickening, and dysfunction), including Libman-Sacks (LS) endocarditis, is frequent in APS, 8 particularly in APS associated with SLE. However, because of contradictory data, HVD has not been accepted as a classification criterion of definite APS.
Although some studies showed an increased frequency of HVD in patients with aPL, other reports did not demonstrate any association. 9 Thus, a preliminary definition of aPL-associated cardiac valve disease has been proposed to facilitate future research in this field. 7 Because aPL are associated with a hypercoagulable state, 10, 11 thrombosis at the valvular surface could be a possible mechanism of HVD in SLE and of LS endocarditis in particular. 12 The importance of such lesions is linked not only to valvular dysfunction but also to the risk of arterial thromboembolism, particularly stroke. 13 Thus, we investigated a possible association between aPL and HVD and/or LS endocarditis in patients with SLE. We conducted a systematic review and meta-analysis of the current literature to estimate the risk for HVD and/or LS endocarditis associated with aPL in SLE patients.
Clinical Perspective on p 224 Methods
We followed the Meta-Analysis of Observational Studies in Epidemiology guidelines during all stages of design, implementation, and reporting of this meta-analysis 14 (see checklist in Table I in the online-only Data Supplement).
Search Strategy and Data Sources
We (S.Z., P.D., D.W.) searched for articles (August 1987 to December 2010) in PubMed (with and without Medical Subject Headings terms), Embase, and the Cochrane Library, without language restriction. Medical Subject Headings terms were as follows: antiphospholipid syndrome, antiphospholipid antibodies, lupus coagulation inhibitor, anticardiolipin antibodies, phospholipids, ␤ 2glycoprotein I, cardiolipins, lupus erythematosus systemic including Libman-Sacks disease, heart valve diseases, endocarditis, and heart valves. We also performed a hand search of major journals and reviewed the reference lists from retrieved articles.
Study Selection
Selection criteria were determined before data collection. To assess the effect estimate for a potential association between aPL (exposure) and HVD (outcome) in SLE patients (study population), we selected the studies that fulfilled our inclusion criteria: study that included SLE patients, defined by American College of Rheumatology criteria, 15, 16 in whom systematic transthoracic and/or transesophageal echocardiography was performed, with descriptions of the exposure to aPL and of the outcome (HVD). Thus, studies with SLE patients involving 2 groups of aPL-positive and aPL-negative patients were analyzed. We included all cohort, case-control, and cross-sectional studies. Reviews, editorials, letters, case reports, unpublished abstracts, and substudies of an eligible study were not included in the selection process. When it was impossible to extract data (even after the authors were contacted), studies were excluded. Two independent reviewers (S.Z., D.W.) screened all identified titles and abstracts and obtained their full-text reports for those considered potentially eligible.
Data Extraction
Data were simultaneously and independently extracted by 2 investigators (S.Z., D.W.), and results were compared. Whenever disagreement occurred, it was resolved by discussion until a consensus was reached. Exposure to aPL (lupus anticoagulant [LA], anticardiolipin antibodies [aCL], and anti-␤ 2 -glycoprotein I antibodies [anti-␤ 2 -GPI]) was defined by results of laboratory tests performed in each study. HVD was considered present if documented as lesions and/or regurgitation and/or stenosis of any valve or any combination of the above. Definition of valve lesions included valve thickness, localized thickening involving the leaflet's proximal or middle portion, irregular nodules, or vegetation/LS endocarditis. 7
Quality Assessment
Clinical, laboratory, echocardiographic, and statistical data of primary articles were reviewed for quality assessment. Studies were evaluated independently by means of a scoring system. Six evaluators were divided into 3 groups of 2 investigators: Clinical data and statistical analysis were reviewed by 2 investigators (S.Z., D.W.), laboratory assessment by 2 hematologists (V.E., T.L.), and echocardiographic data by 2 cardiologists (J.-F.B., C.S.-S.). Any information about authors, journals, and institutions was deleted for the purpose of quality assessment. The scoring system was adapted from the meta-analyses by Wahl et al. 5, 6 The quality assessment form encompassed 64 items distributed in 4 categories: clinical criteria (SLE patients classified or not according to the American College of Rheumatology classification 15, 16 and measure of disease activity); echocardiographic diagnosis of the outcome (HVD) 7 ; definition of the exposure to aPL 7, [17] [18] [19] [20] ; and statistical analysis and control for confounders. Finally, a score was obtained for each category for all studies. We could not perform a complete evaluation of 2 studies 21, 22 because of missing information. The level of agreement between the results of the evaluation among each category was assessed.
Data Synthesis
The odds ratio (OR) was the measure of association used in this meta-analysis. Data were entered in 2ϫ2 contingency tables and were combined. We first performed an analysis based on the main exposure (overall aPL) and the main outcome (HVD). Then we defined the subgroups with respect to exposures of different types of aPL (LA, aCL, and anti-␤ 2 -GPI) and isotypes of aCL or anti-␤ 2 -GPI (IgG and IgM) and different outcome (LS endocarditis). Finally, we performed a sensitivity analysis studying the effect of an exposure to different titers of aCL (low and high aCL titers according to available data published).
Cumulative Meta-Analyses
To assess the contribution of individual studies to cumulatively pooled results, we chose to accumulate data according to (1) descending quality score to allow examination of the impact of successively excluding studies of lesser quality on the overall result;
(2) increasing date of publication to allow assessment of the changes in association between exposure to aPL and HVD in SLE patients over time; and (3) increasing study size to reveal how many patients are needed before statistical significance is obtained.
Statistical Analyses
We obtained pooled risk estimates of risk for HVD with aPL in SLE patients (OR) by using random-effects models, according to the method of DerSimonian and Laird. We assessed heterogeneity among studies with the use of the 2 test, I 2 statistics (lowϭ25.0%; moderateϭ50.0%; highϭ75.0%), and visual inspection of a L'Abbé plot. A cumulative meta-analysis was performed by pooling data again each time a new study was published. Measures of association (OR) and cumulative meta-analyses were performed with the use of a Review Manager (RevMan [computer program] version 5.0; The Nordic Cochrane Centre, The Cochrane Collaboration, 2008, Copenhagen, Denmark). In regard to the scoring system, the level of agreement between the results of the evaluation for each category was assessed by an intraclass correlation coefficient (ICC) with SAS 9.1 software (SAS Institute Inc, Cary, NC). We used the following classification as standards for strength of agreement for the ICC: 0 to 0.50ϭpoor, 0.51 to 0.75ϭmoderate, 0.76 to 1ϭgood. We tested correlations (Spearman) between quality scores and log(OR) of primary studies and risk of HVD and publication year. We examined the extent of publication bias through visual inspection of funnel plot asymmetry with the Begg 23 and the Egger tests. 24 We used Rosenthal's method to estimate the number of nonsignificant unpub- lished (or missing) studies (fail-safe number) that would need to be added to our meta-analysis to reduce our overall statistically significant observed result to nonsignificance.
Results

Literature Flow Chart
Our literature search identified 234 publications, of which 23 unique studies were included in the review 13, 21, 22, [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] (Figure  1 ). Studies were identified with the use of Embase (nϭ115), MEDLINE (nϭ97), Cochrane Library (nϭ0), and hand search (nϭ22) from August 1987 to December 2010.
Study Characteristics
The publication period runs from 1990 to 2007, with the majority of studies published before 1996 (nϭ13) ( Table  1) . Two distinct periods were identified: 1990 -1995 (nϭ13) and 2000 -2007 (nϭ10) . No eligible study was retrieved between 1996 and 1999. Studies were designed as cohort (nϭ7), case-control (nϭ1), and cross-sectional studies (nϭ15). Twenty-one studies determined the pres-ence of aCL, and fewer assayed LA (nϭ13). No selected study determined the presence of anti-␤ 2 -GPI antibodies. All studies investigated the presence of mitral and aortic involvement, and fewer looked for tricuspid (nϭ11) or pulmonary (nϭ2) lesions by transthoracic echocardiography (nϭ20), transesophageal echocardiography (nϭ2), or both (nϭ1). Sample sizes of the 23 studies selected varied from 23 to 200 SLE patients for a total of 1656. In this population of SLE patients, 668 were aPL positive (40%; 95% confidence interval [CI], 38 to 43), and 508 had 1 or several HVD (31%; 95% CI, 28 to 33). Among 21 studies reporting sex ratio and age, the percentage of women was 90.7% (nϭ1528), ranging from 81.3% to 100%. Median age varied from 23 to 50 years, and mean age varied from 25.8 to 44 years.
Quality Assessment
The agreement between evaluators, measured by the ICC, varied from 0.56 (moderate) to 0.84 (good). In the 21 studies in which quality assessment was performed, there was no significant correlation between quality scores and log(OR) of primary studies (R 2 ϭ0.08, Pϭ0. 22) .
Clinical Assessment
The average quality score was 67 of 100, ranging from 25 to 100. Interobserver reliability between investigators was good (ICCϭ0.84). Of the 21 studies fully evaluated, SLE was defined according to the revised criteria of the American College of Rheumatology 15, 16 in 19 studies, and SLE activity was measured in 10 studies. Seven studies described past history of SLE disease and prescribed treatments.
Laboratory Assessment
The average score was 23 of 100, ranging from 3.8 to 61.5. Interobserver reliability between investigators was moderate (ICCϭ0.56). Validated methods for the diagnosis of aCL were used in 15 of the 21 studies and in 6 of the 13 studies for LA. In 9 studies, the authors referred to thresholds validated by workshop recommendations or consensus. 7, 18, 19, 45 In 8 studies, it was noted that aPL were present in plasma on Ն2 occasions according to guidelines. 7
Echocardiographic Assessment
The average score was 41 of 100, ranging from 5 to 76.7. Interobserver reliability between investigators was moderate (ICCϭ0.72). Of 21 studies, 7 studies indicated that ultrasound evaluation was performed by 2 independent reviewers and the results were compared, 3 studies described the use of transesophageal echocardiography, and 13 studies indicated that the flow and hemodynamic consequences of HVD were measured according to validated methods.
Statistical Assessment
The average score was 24 of 100, ranging from 6.7 to 53.3. Interobserver reliability between investigators was moderate (ICCϭ0.57). The studies reviewed were mainly cross-sectional studies (nϭ15) compared with 7 cohort studies and 1 casecontrol study. One study expressed the results with statistical CIs. Ten studies indicated that other causes of HVD (confounding factors) were investigated at the inclusion of patients.
Characteristics of Heart Valve Disease in Systemic Lupus Erythematosus Patients
The types of HVD reported in primary studies are indicated in Table 2 . The most frequent dysfunction associated with defined lesions was regurgitation. Lesions were more frequently located on the mitral and aortic valves.
Risk of Heart Valve Disease Associated With Antiphospholipid Antibodies in Systemic Lupus Erythematosus Patients
Of the 23 included studies representing 1656 SLE patients (Figure 2A ), HVD was present in 43% (95% CI, 40 to 47) of aPL-positive patients and in 22% (95% CI, 19 to 25) of aPL-negative patients. The overall OR for HVD in aPLpositive versus aPL-negative SLE patients was 3.13 (95% CI, 2.31 to 4.24; PϽ0.00001). No significant statistical heterogeneity was found (Pϭ0.11, I 2 ϭ28%), confirmed by visual inspection of the L'Abbé plot (Figure 3 ). This risk was not influenced by the publication year (R 2 ϭ0.02, Pϭ0.54). Thir-teen of the studies reported statistically significant associations between aPL and HVD in SLE patients, and 10 reported no statistical association. When the 2 studies with missing information were excluded from the analysis, 21, 22 from the 21 remaining studies representing 1448 patients, the overall OR was 2.97 (95% CI, 2.18 to 4.05) with no significant statistical heterogeneity (Pϭ0.12, I 2 ϭ27%). The risk of HVD associated with aPL was influenced by the type of study (Table 3) : Whereas the 15 cross-sectional studies included (nϭ1059 patients) tended to show a lower risk (ORϭ2.66 [95% CI, 1.77 to 4.00]), the 7 cohort studies (nϭ527 patients) tended to show a higher risk (ORϭ4.50 [95% CI, 2.84 to 7.12]). Moreover, among the 7 cohort studies, the 5 largest showed a statistically significant association between aPL and HVD in SLE patients, whereas this association was reported by 7 of the 15 cross-sectional studies. The risk of HVD varied depending on aPL types (Table 3) : LA was associated with a higher risk of HVD in SLE patients ( Figure 2B ) (7 studies; nϭ529 patients; proportions of HVD in LA-positive versus LA-negative patients: 36% versus 10%; ORϭ5.88 [95% CI, 2.92 to 11.84]) than aCL (14 studies; nϭ983 patients; proportions of HVD in aCL-positive versus aCL-negative patients: 39% versus 16%; ORϭ3.28 [95% CI, 2.06 to 5.22] ).
In addition, analysis of the subtypes of aCL revealed that IgG aCL were associated with an increased risk of HVD in SLE patients (9 studies; nϭ634 patients; proportions of HVD in IgG aCL-positive versus aCL-negative patients: 40% versus 10%; ORϭ5.63 [95% CI, 3.53 to 8.97]), whereas IgM aCL were not (3 studies; nϭ254 patients; proportions of HVD in IgM aCL-positive versus aCL-negative patients: 23% versus 21%; ORϭ1.67 [95% CI, 0.46 to 6.05]). Sensitivity analysis ( Table 3) showed that high titers of aCL were associated with an increased risk of HVD (4 studies; nϭ348 patients; proportions of HVD in high-titer aCL-positive versus aCLnegative patients: 57% versus 21%; ORϭ5.04 [95% CI, 1.46 to 17.47]) but not low titers (4 studies; nϭ339 patients; proportions of HVD in low-titer aCL-positive versus aCLnegative patients: 36% versus 23%; ORϭ1.72 [95% CI, 0.96 to 3.08]). Like the overall risk of HVD, the risk of LS endocarditis was also strongly associated with aPL in SLE patients ( Figure 2C) : From 9 primary studies representing 799 SLE patients, LS endocarditis was present in 23% (95% 
Cumulative Meta-Analyses
The cumulative meta-analysis of studies arranged by descending quality scores ( Figure 4A ) clearly demonstrated a decreasing estimate of exposure to aPL as lower-qualityscore studies were successively added to the higher-quality-score studies. When arranged by ascending publication date ( Figure 4B ), we found that the risk estimate of HVD was stable from the year 2000. When ordered by increasing study size ( Figure 4C ), we found that the impact of the largest studies 27, 32 was predominant in determining the risk estimate.
Publication Bias
We found no significant evidence for publication bias ( Figure  5 ). Our examination of the funnel plot revealed mild asymmetry, with more negative studies unpublished than positive studies typically seen in publication bias. The Begg test (Pϭ0.27) and the Egger test (Pϭ0.28) did not show any statistical evidence for publication bias. For our collection of studies, the fail-safe number, corresponding to the number of nonsignificant unpublished (or missing) studies that would need to be added to our metaanalysis to reduce our overall statistically significant observed result to nonsignificance, was 634.
Discussion
In this meta-analysis of 23 studies that included 1656 patients with SLE and 508 cases of HVD, we demonstrated, for the first time, a 3-fold higher risk for any heart valve lesion in SLE patients with aPL than in those without. Likewise, patients with aPL also had a 3-fold higher risk for LS endocarditis. Moreover, patients with some subsets of aPL displayed a higher risk profile for valvular lesions. Until now, data were considered contradictory, 9, 32 and the question of the association between aPL and heart valve lesions in SLE patients remained unsolved. Despite a recent systematic review, no estimate of the risk of HVD or LS endocarditis associated with aPL had been obtained. 46 By summarizing all available data from the literature, our meta-analysis, implemented according to the Meta-Analysis of Observational Studies in Epidemiology guidelines, confirmed a clear and substantially higher risk for heart valve lesions associated with aPL in SLE patients.
Quality assessment of studies revealed that these results are based on robust data. The presence of HVD was investigated among Ͼ1600 patients, allowing a precise estimation of the risk with a narrow CI. Overall, quality scores indicated a moderate to good agreement between evaluators. In regard to assessment of outcomes, studies were designed for a reliable evaluation of HVD with the use of transthoracic echocardiography more often than transesophageal echocardiography. However, assessment of exposure to aPL showed some discrepancies between studies, related to inconstant use of current recommendations. 7, 17 Only 8 studies stated that aPL were present in plasma on Ն2 occasions. Furthermore, no study had available data about anti-␤ 2 -GPI antibodies for extraction and synthesis in our meta-analysis. Since 2006, anti-␤ 2 -GPI antibodies have been included as part of the modified classification criteria. 7 They are an independent risk factor for thrombosis in APS. Their association with HVD is not yet established. For these reasons, the lack of data concerning anti-␤ 2 -GPI antibodies is a limitation of primary studies.
Assessment of potential confounding factors such as SLE activity was reported in 48% of evaluated studies. No significant age differences were found between patients with and without HVD or aPL. In the same way, there was no significant difference in sex between patients with and without HVD. Although no study formally investigated a possible difference in sex between aPL-negative and aPLpositive patients, this is very unlikely because the vast majority (Ͼ90%) of the overall population was female. Cross-sectional studies* tended to underestimate the overall risk, whereas case-control and cohort studies 25, 31, 32, [37] [38] [39] [40] 44 tended to estimate a higher risk. This difference may easily be explained by the fact that more outcomes could be measured by a prospective follow-up over years than in cross-sectional studies. Despite their limitations, studies with a lower level of evidence had little impact on the overall results. Finally, we could exclude any significant publication bias.
Our main result is that SLE patients with aPL have a 3-fold higher risk for any heart valve lesion than those without aPL. Our cumulative meta-analyses indicate that this result is consistent with the primary studies that have the highest quality scores and the largest sample sizes. A cumulative meta-analysis according to publication date indicates that this summary estimate has been quite consistent for the last 10 years.
The false-positive rate of a test is a function of the prevalence rate of the trait in the tested population. In SLE *References 13, 21, 22, 26 -30, 33-36, 41-43. patients included in our meta-analysis, the prevalence of aPL was high (40%), as indicated in our aforementioned results. Therefore, because of this high prevalence of aPL in SLE patients, the number of false-positive tests is consequently low.
Finally, computation of a fail-safe number indicates that Ͼ630 studies would be required to reduce our overall statistically significant observed result to nonsignificance. This large number relative to the 23 primary studies included in our meta-analysis strongly sustains our results and allows us to be confident in our conclusions.
The presence of clinical or statistical heterogeneity could explain the differential effects of aPL from one study to another. Thus, in our analysis, we used a random-effects model, assuming that there was some degree of heterogeneity between studies. However, no significant statistical heterogeneity was detected, which allowed the pooling of studies in our analysis. Moreover, the majority of studies (21 of 23) determined the presence of aCL as exposure.
In a subgroup analysis, we identified a 3.5-fold higher risk for LS endocarditis in SLE patients with aPL than in those without. Although LS endocarditis was first described in 1924 in 4 patients with SLE, 47 its etiopathogenic process is still controversial. Inflammatory as well as thrombotic mech-anisms in the presence of aPL have been hypothesized. 12 Ziporen et al 48 showed deposits of aPL and complement components on the deformed heart valves obtained from patients with APS, both primary and associated with SLE. These data may suggest a pathogenetic role for aPL in the development of valve lesions and indicate that aPL have a biological plausibility as a risk factor for HVD. 49 Moreover, Blank et al 50 detected anti-␤ 2 -GPI antibodies on deformed valves from a patient with APS and showed that at least 2 ␤ 2 -GPI-related peptides were target epitopes for these antibodies. These peptides shared a common sequence with different bacterial and viral antigens. On the basis of these studies, the authors raised the possibility that LS nonbacterial endocarditis may have an infectious origin. On the basis of literature and our findings, we can assume that aPL have a key role in the pathogenic process leading to valve destruction in SLE patients, which supports the concept of thrombotic manifestations on valves due to hypercoagulability. However, additional studies using novel techniques such as thrombin-generation tests 10 are needed to determine the respective roles of hypercoagulability and inflammatory mechanisms and their potential interaction in regard to LS endocarditis in patients with SLE.
We have shown that the risk for HVD was different for different subtypes of aPL. Whereas both LA and IgG aCL were associated with a risk at least 5.5 times higher for HVD in SLE patients compared with noncarriers, IgM aCL were not associated with an increased risk for HVD. The risk associated with aPL subsets and other manifestations is somewhat different: For example, the LA effect was different from that of any aCL for venous thromboembolism. Whereas patients with SLE and LA are at Ϸ6 times greater risk for venous thromboembolism than patients without LA, patients with SLE and aCL are at Ϸ2 times greater risk for venous thromboembolism than patients without aCL. 5 The fact that the risk conferred by LA and IgG aCL is comparable in the context of HVD may suggest that these 2 different tests identify similar if not the same patients in the primary studies.
By a sensitivity analysis, we have also shown that high aCL titers were associated with a 5-fold higher risk for HVD, which was not the case for patients with low titers. Likewise, in another setting, it was demonstrated for venous thromboembolism that only high aCL titers were associated with an increased risk for events. 6 Our systematic review and meta-analysis have some limitations because of the primary studies. First, the included studies were mainly case-control or cross-sectional studies rather than cohort studies, which did not have the same risk estimates. Second, future studies are needed to assess whether HVD is associated with anti-␤ 2 -GPI antibodies in SLE patients because no study included in this analysis measured these antibodies.
The results of this meta-analysis seem to be robust and could be generalized to the type of patients studied in the primary studies (ie, patients referred to tertiary care centers). However, it may be premature to apply the results to all SLE patients, especially patients with newly diagnosed diseases, until further studies are conducted. In particular, inception cohort studies of SLE patients assembled at a common time early in the development of their disease should be particularly useful to confirm the causal effect between exposure to aPL/anti-protein antibodies 61,62 and occurrence of HVD in SLE patients. 7 The International Consensus 7 published in 2006 provided a relevant definition of HVD in APS but recommended against its adoption as a criterion. This choice was motivated by the existence of contradictory data at the time. We demonstrated a 3to 5.5-fold higher risk for HVD in aPL-positive compared with aPL-negative SLE patients and an even higher risk associated with LA, comparable to the risk of venous thromboembolism or obstetric manifestations associated with LA, 3,5,6 these manifestations being currently part of the clinical criteria for definite APS. In light of our results and taking into account the magnitude of the association, HVD (including LS endocarditis) should be considered as a criterion of definite APS.
In conclusion, our systematic review and meta-analysis indicate that aPL are associated with a 3-fold higher risk for HVD (including LS endocarditis) in SLE patients. These findings provide the strongest evidence to date of the association between aPL and HVD and of its magnitude. Thus, aPL testing should be required in SLE patients presenting with HVD and/or LS endocarditis. Furthermore, in the clinical setting, these results should lead clinicians to perform systematic echocardiographic examinations in patients with SLE and aPL, even without a history of valve dysfunction, to detect patients with HVD or LS endocarditis who are at higher risk for arterial thrombosis.
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